Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion
May 29, 2018 07:00 ET
|
Axovant Sciences Ltd.
Gavin Corcoran, current Chief Medical Officer of Allergan plc, to join Axovant as EVP of R&DMichael Hayden, former Chief Scientific Officer and President of Global R&D at Teva, to serve as...
Axovant Sciences Announces Changes to Management Team and Board of Directors
February 12, 2018 07:00 ET
|
Axovant Sciences Ltd.
Dr. David Hung resigns as CEO and continues as scientific advisor to Roivant family of companiesDr. Pavan Cheruvu appointed as CEO of AxovantDr. Roger Jeffs, former President and co-CEO of United...
CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
January 09, 2018 07:00 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced a correction to the data related to the Company’s investigational drug nelotanserin previously...
Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
January 08, 2018 07:00 ET
|
Axovant Sciences Ltd.
-- Intepirdine Program to be Discontinued Based on MINDSET, HEADWAY, and Gait and Balance Study Results ---- Company to Advance to Larger Confirmatory Nelotanserin DLB Study Focused on Motor Function...
Axovant to Present at 36th Annual J.P. Morgan Healthcare Conference
January 05, 2018 07:00 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that its Chief Executive Officer David Hung, MD, will be presenting at the 36th Annual J.P....
Axovant Announces Second Fiscal Quarter Financial Results and Corporate Updates
November 02, 2017 16:30 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq:AXON) today announced financial results for its second fiscal quarter and first half ended September 30, 2017, and...